Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD

References

• VestboJHurdSSAgustiAGGlobal strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: GOLD executive summaryAm J Respir Crit Care Med2013187434736522878278
   PubMed Web of Science ®Google Scholar
• CazzolaMPageCPCalzettaLMateraMGPharmacology and therapeutics of bronchodilatorsPharmacol Rev201264345050422611179
   PubMed Web of Science ®Google Scholar
• ColeridgeHMColeridgeJCSchultzHDAfferent pathways involved in reflex regulation of airway smooth musclePharmacol Ther19894211632657805
   PubMed Web of Science ®Google Scholar
• GronebergDAQuarcooDFrossardNNeurogenic mechanisms in bronchial inflammatory diseasesAllergy200459111139115215461593
   PubMed Web of Science ®Google Scholar
• GrossNJCoESkorodinMSCholinergic bronchomotor tone in COPD: estimates of its amount in comparison with that in normal subjectsChest19899659849872805869
   PubMed Web of Science ®Google Scholar
• HallIPSecond messengers, ion channels and pharmacology of airway smooth muscleEur Respir J20001561120112710885434
   PubMed Web of Science ®Google Scholar
• PelaiaGRendaTGallelliLMolecular mechanisms underlying airway smooth muscle contraction and proliferation: implications for asthmaRespir Med200810281173118118579364
   PubMed Web of Science ®Google Scholar
• BerridgeMJInositol trisphosphate and calcium signalingNature199336164103153258381210
   PubMed Web of Science ®Google Scholar
• SomlyoAPSomlyoAVSignal transduction and regulation in smooth muscleNature199437265032312367969467
   PubMed Web of Science ®Google Scholar
• ProfitaMGiorgiRDSalaAMuscarinic receptors, leukotriene B4 production, and neutrophilic inflammation in COPD patientsAllergy200560111361136916197467
   PubMed Web of Science ®Google Scholar
• CasarosaPKiechleTSiegerPThe constitutive activity of the human muscarinic M3 receptor unmasks differences in the pharmacology of anticholinergicsJ Pharmacol Exp Ther2010333120120920035022
   PubMed Web of Science ®Google Scholar
• ChibaYMurataMUshikuboHEffect of cigarette smoke exposure in vivo on bronchial smooth muscle contraction in vitro in ratsAm J Respir Cell Mol Biol200533615741581
   Web of Science ®Google Scholar
• HottaKEmalaCWHirshmanCATNF-α up-regulates Giα and Gqα protein expression and function in human airway smooth muscle cellsAm J Physiol19992763 Pt 1L405L41110070103
   PubMedGoogle Scholar
• BarnesPJBiochemical basis of asthma therapyJ Biol Chem201128638328993290521799015
   PubMed Web of Science ®Google Scholar
• DisseBSpeckGARomingerKLTiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung diseaseLife Sci1999646–745746410069510
   PubMed Web of Science ®Google Scholar
• BarnesPJThe pharmacological properties of tiotropiumChest20001172 Suppl63S66S10673478
   PubMed Web of Science ®Google Scholar
• CazzolaMPageCPRoglianiPMateraMGβ2-Agonist therapy in lung diseaseAm J Respir Crit Care Med2013187769069623348973
   PubMed Web of Science ®Google Scholar
• MuruganandanSJayaramLProfile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPDInt J Chron Obstruct Pulmon Dis2015101179118926124657
   PubMed Web of Science ®Google Scholar
• TautermannCSKiechleTSeeligerDMolecular basis for the long duration of action and kinetic selectivity of tiotropium for the muscarinic M3 receptorJ Med Chem201356218746875624088171
   PubMed Web of Science ®Google Scholar
• CasarosaPBouyssouTGermeyerSPreclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugsJ Pharmacol Exp Ther2009330266066819478135
   PubMed Web of Science ®Google Scholar
• KistemakerLEMGosensRAcetylcholine beyond bronchoconstriction: roles in inflammation and remodelingTrends Pharmacol Sci201536316417125511176
   PubMed Web of Science ®Google Scholar
• ScullionJEThe development of anticholinergics in the management of COPDInt J Chron Obstruct Pulmon Dis200721334018044064
   PubMedGoogle Scholar
• RestrepoRDUse of inhaled anticholinergic agents in obstructive airway diseaseRespir Care200752783385117594728
   PubMed Web of Science ®Google Scholar
• AnzuetoATashkinDMenjogeSOne-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropiumPulm Pharmacol Ther2005182758115649848
   PubMed Web of Science ®Google Scholar
• TashkinDPCelliBSennSA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med2008359151543155418836213
   PubMed Web of Science ®Google Scholar
• CelliBZuWallackRWangSImprovement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumesChest200312451743174814605043
   PubMed Web of Science ®Google Scholar
• O’DonnellDEFlugeTGerkenFEffects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPDEur Respir J200423683284015218994
   PubMed Web of Science ®Google Scholar
• WedzichaJADecramerMSeemungalTAThe role of bronchodilator treatment in the prevention of exacerbations of COPDEur Respir J20124061545155422835613
   PubMed Web of Science ®Google Scholar
• WilkinsonTMHurstJRPereraWREffect of interactions between lower airway bacterial and rhinoviral infections in exacerbations of COPDChest2006129231732416478847
   PubMed Web of Science ®Google Scholar
• BatemanEDRennardSBarnesPJAlternative mechanisms for tiotropiumPulm Pharmacol Ther200922653354219635581
   PubMed Web of Science ®Google Scholar
• MeursHDekkersBGJMaarsinghHMuscarinic receptors on airway mesenchymal cells: novel findings for an ancient targetPulm Pharmacol Ther201326114515522842340
   PubMed Web of Science ®Google Scholar
• PapiABellettatoCMBraccioniFInfections and airway inflammation in chronic obstructive pulmonary disease severe exacerbationsAm J Respir Crit Care Med2006173101114112116484677
   PubMed Web of Science ®Google Scholar
• BuhlingFLiederNKuhlmannUCTiotropium suppresses acetylcholine-induced release of chemotactic mediators in vitroRespir Med2007101112386239417761412
   PubMed Web of Science ®Google Scholar
• SantusPBuccellatiCCentanniSBronchodilators modulate inflammation in chronic obstructive pulmonary diseasePharmacol Res201266434334822659487
   PubMed Web of Science ®Google Scholar
• WedzichaJACalverleyPMSeemungalTAThe prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromideAm J Respir Crit Care Med20081771192617916806
   PubMed Web of Science ®Google Scholar
• VogelmeierCHedererBGlaabTTiotropium versus salmeterol for the prevention of exacerbations of COPDN Engl J Med2011364121093110321428765
   PubMed Web of Science ®Google Scholar
• DecramerMLChapmanKRDahlROnce-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomized, blinded, parallel-group studyLancet Respir Med20131752453324461613
   PubMed Web of Science ®Google Scholar
• BouyssouTCasarosaPNalineEPharmacological characterization of olodaterol, a novel inhaled β2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical modelsJ Pharmacol Exp Ther20103341536220371707
   PubMed Web of Science ®Google Scholar
• CasarosaPKollakIKiechleTFunctional and biochemical rationales for the 24-hour-long duration of action of olodaterolJ Pharmacol Exp Ther2011337360060921357659
   PubMed Web of Science ®Google Scholar
• van NoordJASmeetsJJDrenthBM24-hour bronchodilation following a single dose of the novel β2-agonist olodaterol in COPDPulm Pharmacol Ther201124666667221839850
   PubMed Web of Science ®Google Scholar
• Maleki-YazdiMRBeckEHamiltonAMA randomised, placebo-controlled, Phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-acting β2-agonist, for 4 weeks in patients with chronic obstructive pulmonary diseaseRespir Med2015109559660525829298
   PubMed Web of Science ®Google Scholar
• FergusonGTFeldmanGJHofbauerPEfficacy and safety of olodaterol once daily delivered by Respimat in patients with GOLD 2–4 COPD: results from two replicate 48-week studiesInt J Chron Obstruct Pulmon Dis2014962964524966672
   PubMed Web of Science ®Google Scholar
• KochAPizzichiniEHamiltonALung function efficacy and symptomatic benefit of olodaterol once daily delivered by Respimat in patients with GOLD 2–4 COPD: results from two replicate 48-week studiesInt J Chron Obstruct Pulmon Dis2014969771425045258
   PubMed Web of Science ®Google Scholar
• FeldmanGJBernsteinJAHamiltonAThe 24-h FEV1 time profile of olodaterol once daily via Respimat and formoterol twice daily via Aerolizer in patients with GOLD 2–4 COPD: results from two replicate 6-week crossover studiesSpringerPlus2014341925187881
   PubMedGoogle Scholar
• JoosJFAumannJLCoeckCA randomised, double-blind, four-way, crossover trial comparing the 24-h FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with chronic obstructive pulmonary diseaseRespir Med2015109560661525776199
   PubMed Web of Science ®Google Scholar
• RoskellNSAnzuetoAHamiltonAOnce-daily long-acting β-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterolInt J Chron Obstruct Pulmon Dis2014981382425114521
   PubMed Web of Science ®Google Scholar
• McGarveyLNiewoehnerDMagderSOne-year safety of olodaterol once daily via Respimat in patients with GOLD 2–4 chronic obstructive pulmonary disease: results of a pre-specified pooled analysisCOPD201510.3109/15412555.2014.991864
   PubMedGoogle Scholar
• HoldenNSBellMJRiderCFβ2-Adrenoceptor agonist-induced RGS2 expression is a genomic mechanism of bronchoprotection that is enhanced by glucocorticoidsProc Natl Acad Sci U S A201110849197131971822080612
   PubMed Web of Science ®Google Scholar
• PelaiaGMarsicoSARegulation of β2-adrenergic receptors and the implications for bronchial asthma: an updateMonaldi Arch Chest Dis19944921251308049696
   PubMedGoogle Scholar
• ChuangTTIacovelliLSalleseMG protein-coupled receptors: heterologous regulation of homologous desensitization and its implicationsTrends Pharmacol Sci199617114164218990958
   PubMed Web of Science ®Google Scholar
• PennRBEmbracing emerging paradigms of G protein-coupled receptor agonism and signaling to address airway smooth muscle pathobiology in asthmaNaunyn Schmiedebergs Arch Pharmacol2008378214916918278482
   PubMed Web of Science ®Google Scholar
• MateraMGPageCVCazzolaMNovel bronchodilators for the treatment of chronic obstructive pulmonary diseaseTrends Pharmacol Sci201132849550621683458
   PubMed Web of Science ®Google Scholar
• BarnesPJDistribution of receptor targets in the lungProc Am Thorac Soc20041134535116113456
   PubMedGoogle Scholar
• ZuWallackRAllenLHernandezGEfficacy and safety of combining olodaterol Respimat and tiotropium HandiHaler in patients with COPD: results of two randomized, double-blind, active controlled studiesInt J Chron Obstruct Pulmon Dis201491133114425342898
   PubMed Web of Science ®Google Scholar
• BuhlRMaltaisFAbrahamsRTiotropium and olodaterol fixed-dose combinations versus mono-components in COPD (GOLD 2–4)Eur Respir J201545496997925573406
   PubMed Web of Science ®Google Scholar
• RabeKFTreatment of COPD and the TOnado trial: a tempest in a teapot?Eur Respir J201545486987125829428
   PubMed Web of Science ®Google Scholar
• FergusonGTFlezarMKornSEfficacy of tiotropium + olodaterol in patients with chronic obstructive pulmonary disease by initial severity and treatment intensity: a post hoc analysisAdv Ther201532652353626112656
   PubMed Web of Science ®Google Scholar
• DecramerMCelliBKestenSEffect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomized controlled trialLancet200937496961171117819716598
   PubMed Web of Science ®Google Scholar
• BridevauxP-OGerbaseMWProbst-HenschNMLong-term decline in lung function, utilization of care and quality of life in modified GOLD stage 1 COPDThorax200863976877418505800
   PubMed Web of Science ®Google Scholar
• VestboJEdwardsLDScanlonPDChanges in forced expiratory volume in 1 second over time in COPDN Engl J Med2011365131184119221991892
   PubMed Web of Science ®Google Scholar
• LangePCelliBAgustiALung-function trajectories leading to chronic obstructive pulmonary diseaseN Engl J Med2015373211112226154786
   PubMed Web of Science ®Google Scholar
• BeehK-MWestermanJKirstenA-MThe 24-hour lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary diseasePulm Pharmacol Ther201532535925956072
   PubMed Web of Science ®Google Scholar
• MaltaisFIturriJGKirstenAEffects of 12 weeks of once-daily tiotropium and olodaterol fixed-dose combination on exercise endurance in patients with COPDThorax201469Suppl 2A186A187
   Google Scholar
• CazzolaMRoglianiPOraJMateraMGOlodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary diseaseExpert Rev Clin Pharmacol20158552953926294073
   PubMed Web of Science ®Google Scholar
• BrandPHedererBAustenGHigher lung deposition with Respimat soft mist inhaler than HFA-MDI in COPD patients with poor techniqueInt J Chron Obstruct Pulmon Dis20083476377019281091
   PubMedGoogle Scholar
• DalbyRNEicherJZierenbergBDevelopment of Respimat soft mist inhaler and its clinical utility in respiratory disordersMed Devices20114145155
   Google Scholar
• PitcairnGReaderSPaviaDDeposition of corticosteroid aerosol in the human lung by Respimat soft mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhalerJ Aerosol Med200518326427216181001
   PubMedGoogle Scholar
• DekhuijzenPNRVinckenWVirchowJCPrescription of inhalers in asthma and COPD: towards a rational, rapid and effective approachRespir Med2013107121817182124120398
   PubMed Web of Science ®Google Scholar
• MathioudakisAGKanavidisPChatzimavridou-GrigoriadouVTiotropium HandiHaler improves the survival of patients with COPD: a systematic review and meta-analysisJ Aerosol Med Pulm Drug Deliv2014271435023521168
   PubMed Web of Science ®Google Scholar
• MathioudakisAGMastorisIChatzimavridou-GrigoriadouVThe risk of tachyarrhythmias in patients with moderate-to-severe chronic kidney disease receiving tiotropium bromideInt J Cardiol201519710510626142194
   PubMed Web of Science ®Google Scholar
• CalzettaLMateraMGCazzolaMPharmacological interaction between LABAs and LAMAs in the airways: optimizing synergyEur J Pharmacol201576116817325981302
   PubMed Web of Science ®Google Scholar